Fatty acid synthase: Association with insulin resistance, type 2 diabetes, and cancer

Clinical Chemistry

Volumn 55, Issue 3, 2009, Pages 425-438

  Menendez, Javier A ^a   Vazquez Martin, Alejandro ^a   Ortega, Francisco Jose ^b   Fernandez Real, Jose Manuel ^a,b  

^a HOSPITAL JOSEP TRUETA   (Spain)

^b Instituto de Salud Carlos III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

FAT; FATTY ACID; FATTY ACID SYNTHASE; FATTY ACID SYNTHASE INHIBITOR; GLUCOSE; INSULIN; INSULIN SENSITIZING AGENT; METFORMIN; PLACEBO; SULFONYLUREA;

ADIPOSE TISSUE; BREAST CANCER; CANCER RISK; CLINICAL STUDY; CLINICAL TRIAL; ENERGY; ENERGY EXPENDITURE; ENZYME ACTIVITY; ENZYME STRUCTURE; EXPERIMENTAL STUDY; FATTY ACID SYNTHESIS; GENE MUTATION; GENETICS; GLUCOSE HOMEOSTASIS; HISTORY; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; INTERVENTION STUDY; LIFESTYLE; LIPOGENESIS; LIVER; MASS; METABOLIC DISORDER; MODULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PATHOGENESIS; REVIEW; ADIPOCYTE; ANIMAL; CHEMISTRY; ENZYMOLOGY; METABOLISM; NEOPLASM;

ADIPOCYTES; ANIMALS; DIABETES MELLITUS, TYPE 2; FATTY ACID SYNTHETASE COMPLEX; GLUCOSE; HUMANS; INSULIN RESISTANCE; NEOPLASMS;

EID: 62149134185     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2008.115352     Document Type: Review

References (26)

1. Spencer CA, LoPresti JS, Patel A, Guttler RB, Eigen A, Shen D, et al. Applications of a new chemiluminometric thyrotropin assay to subnor- mal measurement. J Clin Endocrinol Metab 1990; 70:453-60.
2. 3 in normal subjects: a clue to the understanding of subclinical thyroid disease. J Clin Endocrinol Metab 2002;87:1068-72.
3. Fatourechi V, Klee GG, Grebe SK, Bahn RS, Bren- nan MD, Hay ID, et al. Effects of reducing the upper limit of normal TSH values. JAMA 2003; 290:3195-6.
4. Surks MI, Goswami G, Daniels GH. The thyro- tropin reference range should remain unchanged. J Clin Endocrinol Metab 2005;90:5489-96.
5. Wartofsky L, Dickey RA. The evidence for a nar- rower thyrotropin reference range is compelling. J Clin Endocrinol Metab 2005;90:5483-8.
6. Fatourechi V. Upper limit of a normal serum thyroid-stimulating hormone: a moving and now an aging target? J Clin Endocrinol Metab 2007; 92:4560-2.
7. Biondi B, Cooper D. The clinical significance of subclinical thyroid dysfunction. Endocr Rev 2008; 29:76-131.
8. Surks MI, Hollowell JG. Age-specific distribution of serum thyrotropin and antithyroid antibodies in the US population: implications for the preva- lence of subclinical hypothyroidism. J Clin Endo- crinol Metab 2007;92:4575-82.
9. Sawin CT, Geller A, Wolf PA, Belanger AJ, Baker E, Bacharach P, et al. Low serum thyrotropin concentrations as a risk factor for atrial fibrilla- tion in older persons. N Engl J Med 1994;331: 1249-52.
10. Auer J, Scheibner P, Mische T, Langsteger W, Eber O, Eber B. Subclinical hyperthyroidism as a risk factor for atrial fibrillation. Am Heart J 2001;142: 838-42.
11. Cappola AR, Fried LP, Arnold AM, Danese MD, Kuller LH, Burke GL, et al. Thyroid status, cardio- vascular risk, and mortality in older adults. JAMA 2006;295:1033-41.
12. Völzke H, Schwahn C, Wallaschofski H, Dörr M. Review: the association of thyroid dysfunction with all-cause and circulatory mortality: Is there a causal relationship? J Clin Endocrinol Metab 2007;92:2421-9.
13. Parle JV, Maisonneuve P, Sheppard MC, Boyle P, Franklyn JA. Prediction of all-cause and cardio- vascular mortality in elderly people from one low serum thyrotropin result: a 10-year cohort study. Lancet 2001;358:861-5.
14. Gussekloo J, van Exel E, de Craen AJ, Meinders AE, Frölich M, Westendorp RGJ. Thyroid status, disability and cognitive function, and survival in old age. JAMA 2004;292:2591-9.
15. Van den Beld AW, Visser TJ, Feelders RA, Grobbee DE, Lamberts SWJ. Thyroid hormone concentrations, disease, physical function, and mortality in elderly men. J Clin Endocrinol Metab 2005;90:6403-9.
16. Walsh JP, Bremner AP, Bulsara MK, O'Leary P, Leedman PJ, Feddema P, Michelangeli V. Subclin- ical thyroid dysfunction as a risk factor for car- diovascular disease. Arch Intern Med 2005;165: 2467-72.
17. Surks MI, Ortiz E, Daniels GH, Sawin CT, Col NF, Cobin RH, et al. Subclinical thyroid disease: sci- entific review and guidelines for diagnosis and management. JAMA 2004;291:228-38.
18. Cooper DS. Approach to the patient with subclin- ical hyperthyroidism. J Clin Endocrinol Metab 2007;92:3-9.
19. Toft AD. Subclinical hyperthyroidism. N Engl J Med 2001;345:512-6.
20. Hollowell JG, Staehling NW, Flanders WD, Han- non WH, Gunter EW, Spencer CA, et al. Serum TSH, T4, and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab 2002;87: 489-99.
21. Lazarus JH, Kaklamanou M. Significance of low thyroid-stimulating hormone in pregnancy. Curr Opin Endocrinol Diabetes Obes 2007;14:389-92.
22. Baloch Z, Carayon P, Conte-Devolx B, Demers LM, Feldt-Rasmussen U, Henry JF, et al. Labora- tory medicine practice guidelines. Laboratory sup- port for the diagnosis and monitoring of thyroid disease. Thyroid 2003;13:3-126.
23. Rawlins ML, Roberts WL. Performance charac- teristics of six third-generation assays for thy- roid-stimulating hormone. Clin Chem 2004;50: 2338-44.
24. Beckett G, MacKenzie F. Thyroid guidelines - are thyroid stimulating hormone assays fit for the purpose? Ann Clin Biochem 2007;44:203-8.
25. Kratzsch J, Fiedler GM, Leichtle A, Brügel M, Buchbinder S, Otto L, et al. New references inter- vals for thyrotropin and thyroid hormones based on National Academy of Clinical Biochemistry criteria and regular ultrasonography of the thy- roid. Clin Chem 2005;51:1480-6.
26. Knudsen N, Bülow I, Jørgensen T, Laurberg P, Ovesen L, Perrild H. Comparative study of thyroid function and types of thyroid dysfunction in two areas in Denmark with slightly different iodine status. Eur J Endocrinol 2000;143:485-91.